BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 21278242)

  • 21. A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
    Iyer G; Morris MJ; Rathkopf D; Slovin SF; Steers M; Larson SM; Schwartz LH; Curley T; DeLaCruz A; Ye Q; Heller G; Egorin MJ; Ivy SP; Rosen N; Scher HI; Solit DB
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1089-97. PubMed ID: 22124669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
    Wong C; Chen S
    Cancer Res; 2009 Nov; 69(22):8670-7. PubMed ID: 19861537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.
    Wagner AJ; Chugh R; Rosen LS; Morgan JA; George S; Gordon M; Dunbar J; Normant E; Grayzel D; Demetri GD
    Clin Cancer Res; 2013 Nov; 19(21):6020-9. PubMed ID: 24045182
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
    Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
    Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of heat shock protein (molecular weight 90 kDa) attenuates proinflammatory cytokines and prevents lipopolysaccharide-induced liver injury in mice.
    Ambade A; Catalano D; Lim A; Mandrekar P
    Hepatology; 2012 May; 55(5):1585-95. PubMed ID: 22105779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
    Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
    Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance.
    Glaze ER; Lambert AL; Smith AC; Page JG; Johnson WD; McCormick DL; Brown AP; Levine BS; Covey JM; Egorin MJ; Eiseman JL; Holleran JL; Sausville EA; Tomaszewski JE
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):637-47. PubMed ID: 15986212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
    Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors.
    Aregbe AO; Sherer EA; Egorin MJ; Scher HI; Solit DB; Ramanathan RK; Ramalingam S; Belani CP; Ivy PS; Bies RR
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):201-5. PubMed ID: 22450873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Solit DB; Ivy SP; Kopil C; Sikorski R; Morris MJ; Slovin SF; Kelly WK; DeLaCruz A; Curley T; Heller G; Larson S; Schwartz L; Egorin MJ; Rosen N; Scher HI
    Clin Cancer Res; 2007 Mar; 13(6):1775-82. PubMed ID: 17363532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
 being resistant to EGFR-TKI].
    Zhao L; Cao F
    Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):778-82. PubMed ID: 25404267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
    Weigel BJ; Blaney SM; Reid JM; Safgren SL; Bagatell R; Kersey J; Neglia JP; Ivy SP; Ingle AM; Whitesell L; Gilbertson RJ; Krailo M; Ames M; Adamson PC
    Clin Cancer Res; 2007 Mar; 13(6):1789-93. PubMed ID: 17363534
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
    Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
    Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
    Koll TT; Feis SS; Wright MH; Teniola MM; Richardson MM; Robles AI; Bradsher J; Capala J; Varticovski L
    Mol Cancer Ther; 2008 Jul; 7(7):1985-92. PubMed ID: 18645008
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of heat shock protein 90 alleviates steatosis and macrophage activation in murine alcoholic liver injury.
    Ambade A; Catalano D; Lim A; Kopoyan A; Shaffer SA; Mandrekar P
    J Hepatol; 2014 Oct; 61(4):903-11. PubMed ID: 24859453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of heat shock protein (Hsp) 90 potentiates the antiproliferative and pro-apoptotic effects of 2-(4'fluoro-phenylamino)-4H-1,3-thiazine[6,5-b]indole in A2780cis cells.
    Solárová Z; Kello M; Varinská L; Budovská M; Solár P
    Biomed Pharmacother; 2017 Jan; 85():463-471. PubMed ID: 27887849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.
    Isambert N; Delord JP; Soria JC; Hollebecque A; Gomez-Roca C; Purcea D; Rouits E; Belli R; Fumoleau P
    Ann Oncol; 2015 May; 26(5):1005-1011. PubMed ID: 25646368
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 17-DMAG inhibits the multiplication of several Babesia species and Theileria equi on in vitro cultures, and Babesia microti in mice.
    Guswanto A; Nugraha AB; Tuvshintulga B; Tayebwa DS; Rizk MA; Batiha GE; Gantuya S; Sivakumar T; Yokoyama N; Igarashi I
    Int J Parasitol Drugs Drug Resist; 2018 Apr; 8(1):104-111. PubMed ID: 29499568
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 17-DMAG, an Hsp90 inhibitor, ameliorates ovariectomy-induced obesity in rats.
    Tsai YC; Leu SY; Chen SY; Kung CW; Lee YM; Liu YP; Yen MH; Cheng PY
    Life Sci; 2019 Sep; 232():116672. PubMed ID: 31336120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.